Emerging Targets for the Diagnosis of Parkinson's Disease: Examination of Systemic Biomarkers

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2021 May 14

PMID 33988462

Citations 1

Authors

Lara Cheslow

Adam E Snook

Scott A Waldman

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a highly prevalent and irreversible neurodegenerative disorder that is typically diagnosed in an advanced stage. Currently, there are no approved biomarkers that reliably identify PD patients before they have undergone extensive neuronal damage, eliminating the opportunity for future disease-modifying therapies to intervene in disease progression. This unmet need for diagnostic and therapeutic biomarkers has fueled PD research for decades, but these efforts have not yet yielded actionable results. Recently, studies exploring mechanisms underlying PD progression have offered insights into multisystemic contributions to pathology, challenging the classic perspective of PD as a disease isolated to the brain. This shift in understanding has opened the door to potential new biomarkers from multiple sites in the body. This review focuses on emerging candidates for PD biomarkers in the context of current diagnostic approaches and multiple organ systems that contribute to disease.

Citing Articles

GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.

Cheslow L, Byrne M, Kopenhaver J, Iacovitti L, Smeyne R, Snook A NPJ Parkinsons Dis. 2024; 10(1):83.

PMID: 38615030 PMC: 11016112. DOI: 10.1038/s41531-024-00697-z.

References

Blauwendraat C, Nalls M, Singleton A . The genetic architecture of Parkinson's disease. Lancet Neurol. 2019; 19(2):170-178. PMC: 8972299. DOI: 10.1016/S1474-4422(19)30287-X. View

You H, Mariani L, Mangone G, Febvre de Nailly D, Charbonnier-Beaupel F, Corvol J . Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res. 2018; 373(1):111-135. DOI: 10.1007/s00441-018-2813-2. View

Witoelar A, Jansen I, Wang Y, Desikan R, Gibbs J, Blauwendraat C . Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. JAMA Neurol. 2017; 74(7):780-792. PMC: 5710535. DOI: 10.1001/jamaneurol.2017.0469. View

Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C . Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol. 2016; 74(2):163-172. DOI: 10.1001/jamaneurol.2016.4547. View

Leclair-Visonneau L, Clairembault T, Volteau C, Chapelet G, Le Dily S, Vavasseur F . Colonic neuropathology is not associated with autonomic dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2018; 61:224-227. DOI: 10.1016/j.parkreldis.2018.09.021. View

Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T . Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. Gut. 2018; 68(1):18-24. DOI: 10.1136/gutjnl-2017-315666. View

Capaldo C, Nusrat A . Cytokine regulation of tight junctions. Biochim Biophys Acta. 2008; 1788(4):864-71. PMC: 2699410. DOI: 10.1016/j.bbamem.2008.08.027. View

Okamura N, Villemagne V, Drago J, Pejoska S, Dhamija R, Mulligan R . In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010; 51(2):223-8. DOI: 10.2967/jnumed.109.070094. View

10.

Cardaioli G, Ripandelli F, Paolini Paoletti F, Nigro P, Simoni S, Brahimi E . Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study. Eur J Neurol. 2019; 26(11):1370-1376. DOI: 10.1111/ene.13988. View

11.

Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T . Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 1996; 46(3):791-5. DOI: 10.1212/wnl.46.3.791. View

12.

Cervenka S . PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders. Neurosci Lett. 2018; 691:26-34. DOI: 10.1016/j.neulet.2018.03.007. View

13.

Kim A, Nigmatullina R, Zalyalova Z, Soshnikova N, Krasnov A, Vorobyeva N . Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models. Mol Neurobiol. 2018; 56(5):3437-3450. DOI: 10.1007/s12035-018-1315-2. View

14.

Daniele S, Frosini D, Pietrobono D, Petrozzi L, Gerfo A, Baldacci F . α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. Front Mol Neurosci. 2018; 11:53. PMC: 5827358. DOI: 10.3389/fnmol.2018.00053. View

15.

Unger M, Spiegel J, Dillmann K, Grundmann D, Philippeit H, Burmann J . Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. 2016; 32:66-72. DOI: 10.1016/j.parkreldis.2016.08.019. View

16.

LeWitt P, Schultz L, Auinger P, Lu M . CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res. 2011; 1408:88-97. PMC: 4120020. DOI: 10.1016/j.brainres.2011.06.057. View

17.

Almasi-Dooghaee M, Rohani M, Imani A, Nadjafi S, Zamani B . The role of transcranial sonography in differentiation of dementia subtypes: an introduction of a new diagnostic method. Neurol Sci. 2020; 42(1):275-283. DOI: 10.1007/s10072-020-04566-4. View

18.

Hartmann A . Postmortem studies in Parkinson's disease. Dialogues Clin Neurosci. 2011; 6(3):281-93. PMC: 3181805. View

19.

Barber T, Klein J, Mackay C, Hu M . Neuroimaging in pre-motor Parkinson's disease. Neuroimage Clin. 2017; 15:215-227. PMC: 5429242. DOI: 10.1016/j.nicl.2017.04.011. View

20.

Niu M, Li Y, Li G, Zhou L, Luo N, Yao M . A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression. Eur J Neurol. 2020; 27(6):967-974. DOI: 10.1111/ene.14208. View